eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2013
vol. 38
 
Share:
Share:
abstract:

Clinical and immunological analysis of patients with X-linked agammaglobulinemia – single center experience

Małgorzata Pac
,
Bożena Mikołuć
,
Barbara Pietrucha
,
Beata Wolska-Kuśnierz
,
Barbara Piątosa
,
Jacek Michałkiewicz
,
Hanna Gregorek
,
Ewa Bernatowska

(Centr Eur J Immunol 2013; 38 (3): 367-371)
Online publish date: 2013/10/28
View full text Get citation
 
PlumX metrics:
The retrospective analysis of a immunological and clinical survey in 33 boys with definitive diagnosis of X-linked agammaglobulinemia, based on ESID criteria, is presented. Recurrent lower respiratory tract infections were the most common presentation with the onset at the age of 1 year 3 months, when maternal antibodies disappeared. The clinical diagnosis was usually delayed by 2 years and 6 months. The mean IgG level at diagnosis was 1.03 g/l (range 0-4.0 g/l). Mean IgA was 0.039 g/l (range 0-0.38 g/l) and IgM – 0.189 g/l (range 0.021-3.51 g/l). The total number of B cells was decreased and varied between 0-391 cells/µl, with the mean value of 26 cells/µl and 0.65%. The replacement therapy with intravenous immunoglobulin (IVIG) preparation was also delayed, and introduced at the mean age of 3 years 5 months. In some patients it was followed with subcutaneous immunoglobulin (SCIG). The overall prognosis in XLA patients is good if diagnosis and immunoglobulin replacement therapy are done early before the onset of chronic complications. Diagnosis was established through molecular analysis.
keywords:

agammaglobulinemia, primary immunodeficiencies, immunoglobulin replacement therapy, Btk gene

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.